Understanding how SYNCRIP affects prostate cancer treatment resistance
Elucidating the Molecular Role of SYNCRIP in Prostate Cancer and AR Targeted Therapy Resistance
This study is looking at a protein called SYNCRIP to understand why some prostate cancers stop responding to hormone treatments, with the hope of finding new ways to help patients with advanced prostate cancer get better results from their therapies.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11221969 on NIH RePORTER |
What this research studies
This research investigates the role of a protein called SYNCRIP in prostate cancer, particularly in cases where the cancer becomes resistant to hormone therapies. By studying how the loss of SYNCRIP is linked to treatment failure, the researchers aim to uncover the underlying mechanisms of resistance. They will use both laboratory experiments and patient samples to explore how SYNCRIP influences cancer cell behavior and response to therapy. The goal is to identify new therapeutic targets that could improve treatment outcomes for patients with advanced prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with metastatic castration-resistant prostate cancer who are undergoing or have undergone androgen receptor targeted therapy.
Not a fit: Patients with early-stage prostate cancer or those not receiving androgen receptor targeted therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for overcoming treatment resistance in prostate cancer, potentially improving survival rates for patients.
How similar studies have performed: Previous research has shown that targeting molecular mechanisms of therapy resistance can lead to significant advancements in cancer treatment, suggesting a promising avenue for this investigation.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Mu, Ping — Yale University
- Study coordinator: Mu, Ping
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.